Literature DB >> 20307377

Electrophysiological assessment of polyneuropathic involvement in rheumatoid arthritis: relationships among demographic, clinical and laboratory findings.

Ayse Oytun Bayrak1, Dilek Durmus, Yunus Durmaz, Ilknur Demir, Ferhan Canturk, Musa Kazim Onar.   

Abstract

OBJECTIVES: The aims of this study were to electrophysiologically evaluate polyneuropathy in rheumatoid arthritis (RA) patients and to examine the relationships among polyneuropathy and demographic, clinical and laboratory findings. PATIENTS AND METHODS: Sixty consecutive patients (51 women and nine men) with a clinical diagnosis of RA were examined electrophysiologically for the evidence of polyneuropathy. Parameters including age, gender, subcutaneous nodules, erosions, joint deformities, laboratory parameters, duration of RA, as well as dose, duration and type of disease modifying anti-rheumatic drug (DMARD) and steroid usage were recorded. RA activity was assessed using a 28-joint disease activity score (DAS28). The functional status of patients was measured using the health assessment questionnaire (HAQ). The symptoms and signs of polyneuropathy were quantified using the neuropathy symptoms score (NSS) and the neuropathy disability score (NDS), respectively.
RESULTS: Ten patients (17%, eight women and two men) had polyneuropathic involvement as defined by nerve conduction studies (NCS). Two patients had mild symmetric sensory neuropathy and eight patients had mild symmetric sensorimotor axonal polyneuropathy. There was no significant difference in age, gender, subcutaneous nodules, erosions, joint deformities, rheumatoid factor, as well as dose, duration and type of DMARD and steroid therapy administered. We found a significant relationship among polyneuropathy and duration of RA, DAS28, HAQ, as well as abnormal NSS and NDS values. The durations of RA and DAS28 were also associated with a four- and three-fold increase in the risk of polyneuropathy, respectively.
CONCLUSION: Mild symmetric sensory or sensorimotor axonal polyneuropathies are common in RA patients and it is difficult to distinguish the symptoms of polyneuropathy from those of arthritis. An electrophysiological examination should be routinely carried out especially when patients have had a long disease duration and high scores for DAS28, HAQ, NSS and NDS.

Entities:  

Mesh:

Year:  2010        PMID: 20307377     DOI: 10.1179/016164109X12581096870195

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  6 in total

Review 1.  Beyond the joints: neurological involvement in rheumatoid arthritis.

Authors:  Cesar Ramos-Remus; Sergio Duran-Barragan; Jose Dionisio Castillo-Ortiz
Journal:  Clin Rheumatol       Date:  2011-09-20       Impact factor: 2.980

2.  Rheumatoid arthritis-associated spinal neuroarthropathy with double-level isthmic spondylolisthesis.

Authors:  Sang-Il Kim; Young-Hoon Kim; Jae-Won Lee; Won-Woo Kang; Kee-Yong Ha
Journal:  Eur Spine J       Date:  2017-07-28       Impact factor: 3.134

Review 3.  Advances in imaging technologies for the assessment of peripheral neuropathies in rheumatoid arthritis.

Authors:  Josefina Gutiérrez; Hugo Sandoval; Iván Pérez-Neri; Antonio Arauz; Juan Carlos López-Hernández; Carlos Pineda
Journal:  Rheumatol Int       Date:  2021-01-11       Impact factor: 2.631

4.  Assessment of peripheral neuropathy in patients with rheumatoid arthritis who complain of neurologic symptoms.

Authors:  Mi Kyung Sim; Dae-Yul Kim; Jisun Yoon; Dae Hwan Park; Yong-Gil Kim
Journal:  Ann Rehabil Med       Date:  2014-04-29

5.  Prevalence and patterns of peripheral neuropathy in patients of rheumatoid arthritis.

Authors:  Nidhi Kaeley; Sohaib Ahmad; Monika Pathania; Rajesh Kakkar
Journal:  J Family Med Prim Care       Date:  2019-01

6.  Evaluation of peripheral neuropathy in lower limbs of patients with rheumatoid arthritis and its relation to fall risk.

Authors:  Fabio de Araújo Pereira; Mariana de Almeida Lourenço; Marcos Renato de Assis
Journal:  Adv Rheumatol       Date:  2022-03-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.